Freshford Capital Management Has Boosted Akamai Technologies (AKAM) Stake By $3.27 Million; Sage Therapeutics Has 1.49 Sentiment

March 21, 2018 - By Adrian Mccoy

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.61 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Freshford Capital Management Llc increased Akamai Technologies Inc (AKAM) stake by 13.64% reported in 2017Q3 SEC filing. Freshford Capital Management Llc acquired 68,196 shares as Akamai Technologies Inc (AKAM)’s stock declined 24.00%. The Freshford Capital Management Llc holds 568,196 shares with $27.68 million value, up from 500,000 last quarter. Akamai Technologies Inc now has $12.54 billion valuation. The stock increased 0.05% or $0.04 during the last trading session, reaching $73.72. About 493,659 shares traded. Akamai Technologies, Inc. (NASDAQ:AKAM) has declined 6.51% since March 21, 2017 and is downtrending. It has underperformed by 23.21% the S&P500.

Investors sentiment decreased to 0.82 in 2017 Q3. Its down 0.17, from 0.99 in 2017Q2. It dived, as 51 investors sold AKAM shares while 138 reduced holdings. 38 funds opened positions while 150 raised stakes. 138.17 million shares or 0.41% less from 138.74 million shares in 2017Q2 were reported. Alphamark Advisors Lc has invested 0% of its portfolio in Akamai Technologies, Inc. (NASDAQ:AKAM). Retirement Of Alabama owns 83,167 shares. Stifel Financial accumulated 0.04% or 256,735 shares. California-based Lpl Lc has invested 0.01% in Akamai Technologies, Inc. (NASDAQ:AKAM). Moreover, Nikko Asset Mngmt Americas has 0.01% invested in Akamai Technologies, Inc. (NASDAQ:AKAM). Proshare Advisors Limited Liability Company accumulated 0.04% or 84,595 shares. Gateway Investment Advisers Ltd owns 45,068 shares or 0.02% of their US portfolio. Dearborn Partners Lc invested 0.02% of its portfolio in Akamai Technologies, Inc. (NASDAQ:AKAM). Old Mutual Customised Solutions (Proprietary) Ltd holds 2,332 shares. State Treasurer State Of Michigan reported 52,023 shares. Woodstock Corp has invested 0.09% in Akamai Technologies, Inc. (NASDAQ:AKAM). 117,436 are held by Great West Life Assurance Can. Vigilant Mgmt Lc invested in 1,750 shares. Macquarie Gru reported 4,100 shares. Argent Tru has invested 0.08% of its portfolio in Akamai Technologies, Inc. (NASDAQ:AKAM).

Among 30 analysts covering Akamai Tech (NASDAQ:AKAM), 17 have Buy rating, 2 Sell and 11 Hold. Therefore 57% are positive. Akamai Tech had 95 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 18 by Credit Suisse. The rating was downgraded by Pacific Crest to “Sector Weight” on Wednesday, July 27. Piper Jaffray maintained Akamai Technologies, Inc. (NASDAQ:AKAM) rating on Wednesday, September 20. Piper Jaffray has “Buy” rating and $55.0 target. The rating was maintained by Oppenheimer with “Buy” on Wednesday, July 26. The rating was initiated by Stifel Nicolaus with “Hold” on Thursday, March 24. As per Tuesday, February 6, the company rating was maintained by KeyBanc Capital Markets. The stock has “Hold” rating by Robert W. Baird on Thursday, October 19. Nomura maintained Akamai Technologies, Inc. (NASDAQ:AKAM) on Wednesday, October 25 with “Neutral” rating. Cowen & Co maintained Akamai Technologies, Inc. (NASDAQ:AKAM) on Tuesday, February 6 with “Hold” rating. FBR Capital maintained it with “Underperform” rating and $49 target in Thursday, October 29 report.

Since October 2, 2017, it had 1 insider buy, and 7 selling transactions for $4.78 million activity. Another trade for 8,528 shares valued at $565,321 was sold by MCCONNELL RICK M. $564,810 worth of Akamai Technologies, Inc. (NASDAQ:AKAM) was sold by Gemmell James. Another trade for 10,000 shares valued at $662,900 was made by Wheaton William on Monday, December 18. 17,537 shares were bought by LEIGHTON F THOMSON, worth $999,784.

Palo Alto Investors Llc holds 2.07% of its portfolio in Sage Therapeutics, Inc. for 787,251 shares. Bb Biotech Ag owns 1.09 million shares or 1.88% of their US portfolio. Moreover, Oak Ridge Investments Llc has 1.86% invested in the company for 736,709 shares. The Connecticut-based Great Point Partners Llc has invested 1.33% in the stock. New Leaf Venture Partners L.L.C., a New York-based fund reported 44,872 shares.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 EPS, down 21.71% or $0.33 from last year’s $-1.52 per share. After $-1.75 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 3 sales for $27.36 million activity.

The stock decreased 0.09% or $0.15 during the last trading session, reaching $166.3. About 122,124 shares traded. Sage Therapeutics, Inc. (SAGE) has risen 116.45% since March 21, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News